Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
August 22, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today. “In...
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
August 16, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 16 August 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its second...
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients
August 03, 2023 02:00 ET
|
Ultimovacs ASA
The randomized, investigator-initiated FOCUS trial has completed enrollment of 75 patients with recurrent or metastatic head and neck squamous cell carcinoma The study will provide randomized data...
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
June 28, 2023 10:30 ET
|
Ultimovacs ASA
Results from the UV1-103 trial published in Clinical Cancer Research highlight the promising efficacy and safety of UV1 and pembrolizumab in malignant melanoma Biomarker analyses demonstrate...
Ultimovacs’ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award’s Honorary Prize as an Outstanding Pioneer Against Cancer
June 22, 2023 09:30 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE The Honorary Prize is awarded to an individual who has left a remarkable imprint and contributed with notable impact through their dedicated efforts and outstanding...
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine
June 19, 2023 01:00 ET
|
Ultimovacs ASA
All patients in cohort 2 who were alive after 2 years remain alive after 3 years Oslo, 19 June 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology...
Ultimovacs ASA: Mandatory notification of trade by primary insider
June 08, 2023 08:34 ET
|
Ultimovacs ASA
Oslo, 08 June 2023, Board member Ketil Fjerdingen and primary insider in Ultimovacs ASA, has today through Langøya Invest AS bought 7,000 shares in the company at a price of NOK 79.5159 per share....
Ultimovacs ASA: Mandatory notification of trade by primary insider
June 08, 2023 06:22 ET
|
Ultimovacs ASA
Oslo, 8 June 2023, Radforsk Investeringstiftelse, a closely associated party of Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 7,100 shares in the company...
Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma
June 07, 2023 13:08 ET
|
Ultimovacs ASA
The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival (PFS). However, a statistically significant improvement in PFS for patients...
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
May 10, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, May 10, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its first quarter 2023 results today. First...